Pembrolizumab (Keytruda®) is indicated for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||06/12/2017|
|Rapid review completed||21/12/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended|
|Following an amendment of the product license by the EMA, a new rapid review was commissioned by the HSE.|
|Rapid review commissioned||21/06/2018|
|Rapid review received||10/07/2018|
|Rapid review completed||27/07/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies|
The HSE has approved reimbursement following confidential price negotiations – February 2021.